Valuation: Compugen Ltd.

Market Cap 228M 198M 185M 169M 318M 21.79B 323M 2.18B 853M 10.91B 857M 838M 36.38B P/E 2026 *
-9.09x
P/E 2027 * -8.49x
Enterprise Value 228M 198M 185M 169M 318M 21.79B 323M 2.18B 853M 10.91B 857M 838M 36.38B EV / Sales 2026 *
21.3x
EV / Sales 2027 * 29.5x
Free-Float
97.9%
Yield 2026 *
-
Yield 2027 * -
1 day-3.60%
1 week+4.78%
Current month+2.55%
1 month+4.78%
3 months-15.44%
6 months+46.06%
Current year+57.52%
1 week 2.31
Extreme 2.31
2.5
1 month 2.17
Extreme 2.17
2.52
Current year 1.51
Extreme 1.51
3.24
1 year 1.3
Extreme 1.295
3.24
3 years 0.53
Extreme 0.53
3.24
5 years 0.51
Extreme 0.51
7.48
10 years 0.51
Extreme 0.51
19.9
Manager TitleAgeSince
Chief Executive Officer - 2025-09-22
Director of Finance/CFO 42 2024-08-14
Chief Operating Officer 49 2023-12-31
Director TitleAgeSince
Chairman 59 2025-09-22
Director/Board Member 59 2018-06-10
Director/Board Member 70 2018-06-10
Date Insider Type Main position Quantity % Market Cap.
7/29/26 Free

Chief Operating Officer

70,000 0.0740%
7/29/26 Free

Chairman

100,000 0.1058%
7/29/26 Free

Chief Financial Officer

45,500 0.0481%
Change 5-day change 1-year change 3-year change Capi.($)
-3.60%+4.78%+62.84%+117.12% 237M
+1.17%+1.09%+4.03%+15.74% 48.72B
-1.59%+2.12%+460.02%+573.56% 43.99B
-0.85%+7.95%+15.77%+80.09% 40.82B
-0.08%+3.91%+26.96%+9.86% 39.79B
0.00%+3.59%+20.51%+48.00% 32.7B
-3.61%-1.45% - - 16.84B
-2.52%-0.52%+24.35%+118.05% 16.66B
+0.72%+0.31%+4.94%+21.70% 13.95B
-1.09%+5.94%+81.46%+31.15% 13.58B
Average -1.14%+2.86%+77.88%+112.81% 26.73B
Weighted average by Cap. -0.60%+2.45%+97.50%+135.57%

Financials

2026 *2027 *
Net sales 10.72M 9.29M 8.71M 7.94M 14.94M 1.02B 15.18M 103M 40.04M 512M 40.24M 39.37M 1.71B 7.75M 6.72M 6.3M 5.74M 10.8M 740M 10.98M 74.15M 28.95M 370M 29.1M 28.47M 1.24B
Net income -25.11M -21.76M -20.4M -18.6M -35M -2.4B -35.56M -240M -93.78M -1.2B -94.26M -92.21M -4B -27.81M -24.11M -22.6M -20.6M -38.77M -2.65B -39.39M -266M -104M -1.33B -104M -102M -4.43B
Net Debt - -
Logo Compugen Ltd.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Employees
75
Date Price Change Volume
26-08-13 US$2.410 -3.60% 280,002
26-08-12 US$2.500 +4.17% 447,014
26-08-11 US$2.400 +2.56% 297,200
26-08-10 US$2.340 -2.90% 231,428
26-08-07 US$2.410 +4.78% 276,177
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.410USD
Average target price
4.600USD
Spread / Average Target
+90.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CGEN Stock